MicroPort Orthopedics Announces Industry Symposium at American Association of Hip and Knee Surgeons
ARLINGTON, TENNESSEE, October 17, 2017 – MicroPort Orthopedics, a medical device company that develops and manufactures cutting-edge joint replacement implants and approaches, will host an industry symposium at the annual American Association of Hip and Knee Surgeons (AAHKS) meeting titled, “Tackling Your Toughest Cases in the Changing Healthcare Landscape” on Friday, November 3, 2017.
The symposium will feature four surgeon panelists, invited by MicroPort Orthopedics, who will discuss management of the toughest hip and knee replacement cases in an orthopedic landscape that faces evolving healthcare trends including new orthopedic technology and innovation, changing regulations and payment models, and the shift to outpatient care.
“Everyone in the medical device industry recognizes that the healthcare marketplace is evolving at breakneck speed, and we are constantly in pursuit of better and more efficient ways to adapt to these changes,” said Aurelio Sahagun, President, MicroPort Orthopedics. “We’re grateful to have not only a platform at AAHKS to discuss these innovations but also four renowned orthopedic surgeons who can speak to industry trends, best practices, and new approaches to their work.”
The symposium will be moderated by Stephen Murphy, MD, an orthopedic surgeon at New England Baptist Hospital, who will also be speaking about his experience in the Bundled Payments for Care Improvement (BPCI) Initiative. Joining Dr. Murphy will be, Judd Cummings, MD, Jimmy Chow, MD and Nicolas Noiseux, MD, MS, FRCSC. Dr. Cummings, an orthopedic surgeon at Specialty Orthopedic Surgery, will examine key considerations when taking on tough cases. Dr. Chow, a hip & knee specialist at Chow Hip and Knee, will discuss the importance of powerful surgical philosophy for Total Hip Arthroplasty. Dr. Noiseux, an associate professor in the department of Orthopedics and Rehabilitation at the University of Iowa Hospitals and Clinics, will be talking about anterior-posterior stability in complex primary cases. Following the discussion, the surgeons will answer questions asked by the audience.
About MicroPort Orthopedics
Established in January 2014, MicroPort Orthopedics Inc. is the fifth largest multinational producer of hip and knee implants and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative OrthoRecon products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japanese, Latin American and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/ or follow the company on Twitter at @MicroPortOrtho.
About MicroPort Scientific
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.
Forward-Looking Statements
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation
Ryan Donovan | Assistant Account Executive
O: 617-374-8800 x102
M: 857-294-2561
Email: rdonovan@lavoiehealthscience.com | Twitter: @lavoiegroup
LinkedIn: https://www.linkedin.com/company/lavoie-group
Website: http://www.lavoiehealthscience.com
